1. Home
  2. EXR vs ILMN Comparison

EXR vs ILMN Comparison

Compare EXR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extra Space Storage Inc

EXR

Extra Space Storage Inc

HOLD

Current Price

$145.72

Market Cap

30.3B

Sector

Real Estate

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$191.83

Market Cap

26.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXR
ILMN
Founded
1977
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
26.7B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
EXR
ILMN
Price
$145.72
$191.83
Analyst Decision
Buy
Hold
Analyst Count
15
17
Target Price
$144.80
$124.24
AVG Volume (30 Days)
1.3M
2.0M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
4.61%
N/A
EPS Growth
13.90
170.87
EPS
2.39
2.22
Revenue
$3,377,542,000.00
$4,343,000,000.00
Revenue This Year
N/A
$6.47
Revenue Next Year
$3.63
$5.58
P/E Ratio
$62.57
$84.67
Revenue Growth
3.70
N/A
52 Week Low
$125.71
$88.00
52 Week High
$158.88
$207.00

Technical Indicators

Market Signals
Indicator
EXR
ILMN
Relative Strength Index (RSI) 49.94 50.17
Support Level $142.28 $117.64
Resistance Level $151.04 $196.66
Average True Range (ATR) 3.24 7.89
MACD -0.06 -1.77
Stochastic Oscillator 26.14 18.59

Price Performance

Historical Comparison
EXR
ILMN

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: